Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
Colleen F Kelley, Moupali Das, Breno Santos, Ramin Ebrahimi, Marcelo H Losso, Nittaya Phanuphak, Carlos Brites, Karam Mounzer, Cynthia Brinson, Renu Singh, Pedro Cahn, Pamela Wong, Gordon Crofoot, Richard Kaplan, Peter J Ruane, Anthony Mills, Aditya Gaur, Moti Ramgopal, Beatriz Grinsztejn, Jorge Sánchez, Richard M Novak, Kenneth H Mayer, Anchalee Avihingsanon, Valeria D Cantos, Jared M Baeten, Maribel Acevedo-Quiñones, Allison L Agwu, Paul Benson, Jill Blumenthal, Jesse Clark, Meredith Clement, Cathy Creticos, Ricardo S Diaz, Susanne Doblecki-Lewis, Jorge A Gallardo-Cartagena, Shawn Hassler, Juan Carlos Hinojosa, Theo Hodge, Marcus Lacerda, Anthony LaMarca, José Valdez Madruga, Nkosiphile Ndlovu, Alma Perez Rios, Patric Schine, Tanya Schreibman, LaShonda Y Spencer, Olivia T Van Gerwen, Ricardo Vasconcelos, Jose Gabriel Vasquez, Zwelethu Zwane, Stephanie Cox, Chris Deaton, Lillian B Brown, Christoph C Carter, Onyema Ogbuagu
The New England journal of medicine 2025;392(13):1261-1276